Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.
about
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral TherapyFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics
P2860
Q28546430-65054987-A658-4F69-B93E-F72DA97313D4Q28547869-945365AB-5519-4C9B-B76A-0941C709797DQ33775397-A3E1F010-1F99-4720-AC6A-58B352082F1AQ36309602-219E1BDA-AE9E-4DDA-8CDE-70948C1397CDQ36426953-739BC583-E6BF-4056-A260-2C01224F3EB0Q36505387-89C987F5-103D-406B-B9D9-CA7BBF049320Q37328870-F3232E25-1399-453B-8F3C-0901F1999EEDQ38169257-B6D26BDA-DC9B-422E-A099-09AC7FBFC982Q41992990-A155A438-BBD2-4366-B25E-44BDA7B30F6BQ54212183-26DBB28B-6FE7-47D8-B966-172A2DCDA09CQ57403878-1831F0FA-B6BE-438D-B423-6DB379C65C68
P2860
Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Unboosted atazanavir for treat ...... e and recommendations for use.
@en
Unboosted atazanavir for treat ...... e and recommendations for use.
@nl
type
label
Unboosted atazanavir for treat ...... e and recommendations for use.
@en
Unboosted atazanavir for treat ...... e and recommendations for use.
@nl
prefLabel
Unboosted atazanavir for treat ...... e and recommendations for use.
@en
Unboosted atazanavir for treat ...... e and recommendations for use.
@nl
P2093
P2860
P1433
P1476
Unboosted atazanavir for treat ...... e and recommendations for use.
@en
P2093
Carlo Torti
Davide Motta
Diego Ripamonti
Emanuele Focà
P2860
P304
P356
10.2165/11631070-000000000-00000
P577
2012-06-01T00:00:00Z
P6179
1052037427